India's free generic drug program is "a positive step in improving access to health care"

25 July 2012

Recently much attention has been focused on the need to ensure that poor populations have access to generic essential medicines. Actor Aamir Khan has pitched before a parliamentary panel the need to ensure that generic medicines are made available to the poor. In June, the government of India announced that it is setting up a procurement and distribution system intended to provide low income populations with free unbranded generic medicines.

According to Aman Gupta, principal advisor at India Health Progress, an independent call-for-action forum working to improve health care, “Aamir Khan’s comments and the initiatives of the government of India are critically important steps in meeting India’s unmet health needs. A publicly funded drug program for poor populations is essential to reducing the growing social and economic burden of disease in India for the hundreds of millions of Indians who live below the poverty line”

Shift away from communicable diseases

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics